Shanghai United Imaging Healthcare (688271) Q4 2024 earnings summary

Executive summary

• Revenue declined 9.73% year-over-year to RMB 10.3 billion, with net profit down 36.08% to RMB 1.26 billion, mainly due to domestic market contraction and increased R&D investment.

• Despite industry headwinds, market share increased, especially in high-end products, and overseas revenue grew 35.07% to a record 22% of total revenue.

• R&D investment reached RMB 2.26 billion, 21.95% of revenue, supporting product innovation and global expansion.

• The company maintained a strong balance sheet, with total assets up 10.65% to RMB 28.04 billion and net assets up 5.5% to RMB 19.9 billion.

Financial highlights

• Operating cash flow was negative RMB 619 million, reflecting slower sales collection and higher inventory.

• Gross margin improved to 49.4%, and service revenue margin rose to 63.43%.

• Basic and diluted EPS were RMB 1.54, down 35.83% year-over-year.

• R&D capitalization ratio increased to 22.09% from 9.91% last year.

Outlook and guidance

• Management expects industry recovery as domestic policy implementation accelerates and market demand rebounds.

• Continued focus on high-end equipment, AI integration, and global market penetration is expected to drive future growth.

• If profitability continues in 2025, a mid-year dividend is planned, not less than 10% of net profit for the period.